The clinical testing model has a logical structure. A physician identifies a clinical indication, orders the test, the patient completes the collection, and the result informs a clinical decision. This model is effective when it works, and it works well for the majority of diagnostic testing.
It has two structural limits that matter for specialty labs.
First: it requires a physician intermediary. Patients who want advanced health information proactively — who want to understand their cancer risk, their cardiac health, their genetic profile, without waiting for a physician to identify a clinical indication — have no clear pathway in the physician-ordered model.
Second: it assumes the patient will complete the collection. When the collection infrastructure is absent in the patient's geography, the physician order exists but the specimen never arrives. The test never happens.
MAPRx opens a direct-to-patient channel that operates outside the physician-ordered model. Tests are either available at the pharmacy counter — cash-pay, no prescription, no insurance authorization — or the test can be ordered directly from the participating lab directly. Patients who want access to advanced testing can find it where they already go for health products.
For tests that require a blood draw, MAPRx connects patients with MAPs: Medical Access Points/Providers™ near them where a trained, credentialed collector handles the specimen. The same quality standards, the same compliance infrastructure, the same Sticklogistics® training that MOMS' lab clients rely on for physician-ordered collections apply to MAPRx collections.
For specialty labs, MAPRx is a patient acquisition channel. It reaches patients who are actively looking for advanced testing — the ones who don't want to wait for a referral, who are willing to pay directly, and who are making health decisions proactively rather than reactively.
Consumer spending on direct-pay health testing has expanded meaningfully over the past several years. Patients are increasingly comfortable paying out-of-pocket for health information, particularly for tests that address proactive health management rather than acute clinical care. The pharmacy has become a primary health access point for many consumers — a place they trust, visit regularly, and associate with health decisions.
MAPRx is positioned at the intersection of those two trends: advanced diagnostic testing, at the pharmacy, on the patient's timeline.
GRAIL's Galleri® multi-cancer early detection test is the first specialty lab test live on the MAPRx platform. Galleri® screens for signals associated with more than 50 cancer types from a single blood draw. It's designed for people without symptoms who want to know if a cancer signal is present.
For a test explicitly designed for proactive health management in people without a current cancer diagnosis, the pharmacy channel is a natural fit. The people most likely to seek out Galleri® proactively are the same people who take an active role in managing their health — and who visit their pharmacy for health products on a regular basis.
MAPRx is expanding to include test options spanning many areas of health, including: blood panels, genetic testing (including carrier and hereditary risk panels), hormone and thyroid testing, cardiac and metabolic panels, women's health, infectious disease, respiratory and allergy panels, and more.
Patients interested in various test options can register for updates here.
The physician-ordered testing model isn't going anywhere. It remains the primary clinical pathway for specialty diagnostic testing and the foundation of most labs' commercial operations.
MAPRx adds a channel alongside it — one that reaches a patient population that is actively seeking advanced testing, willing to pay directly, and not waiting for the clinical system to catch up with their desire for health information.
The collection infrastructure is the same. The compliance standards are the same. The platform is MOMS. The channel is retail. The patients are already at the pharmacy.